ClinicalTrials.gg
Not yet recruitingNCT07698262NeuroDCDUpdated Nov 3, 2026

Brain-based Prediction of the Dying Duration in Humans After Withdrawal of Life Sustaining Therapies to Inform Donation After Circulatory Death

An observational study in Organ Donation After Circulatory Death, sponsored by University of British Columbia. Not yet recruiting at 13 sites in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of British Columbia · Observational

How we know

Updated Nov 3, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Death with a site in Canada — 6 open to participants now, 9 under way, 1 of them phase 3. Death · Canada.

Planned enrollment
17th of 19
102 · median 417
Started
2027
the only one that year
Observational
19 of 43
3 open now
Registered
43rd of 43
by date

Among the 43 studies in Death with a site in Canada, this one is the 17th largest by planned enrollment of the 19 observational ones that give a count, is the only one that started in 2027, is one of 19 observational ones, and was the 43rd registered.

Death

457 studies on the registry are indexed under Death; 85 are open to participants now.

Browse Death studies →

Open to participants now

6 of the 43 studies in Death with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Death with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to develop a new tool that uses information collected before life-sustaining treatments are withdrawn to better predict whether a patient will die within the time needed for organ donation to be possible. The tool created should help improve planning for organ donation and provide families and healthcare teams with more accurate information.

03

Conditions studied

  • Organ Donation After Circulatory Death

Browse trials for

Keywords

  • Predicting organ donation after circulatory death
  • DCD
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 19;
  2. Eligible for DCD

Exclusion criteria

Exclusion Criteria:

  1. Complete high cervical spinal cord injury (C5 and above)
  2. Pacemaker in situ
  3. Tracheostomy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • The study cohort will consist of patients eligible for donation after circulatory determination of
06

What researchers measure

Primary outcomes

  1. To develop a clinically applicable model to predict dying duration in a cohort of patient eligible for donation after circulatory death

    Specifically, we aim at assessing the predictive ability of blood-based brain biomarkers, optic nerve sheet diameter as measured by head computed tomography (CT) scans as a surrogate of intracranial pressure and autonomic dysfunction as reflected by abnormal heart rate variability (HRV) to predict the dying duration.

    Time frame: The models will be built to predict death within 30, 60 and 120 minutes

Secondary outcomes

  1. Comparison of the brain-to-heart model to existing models

    Our secondary aim will be to compare the created models with available models (e.g., DCD-N, UNOS, Wisconsin) and to physician gestalt

    Time frame: The models will be compared for death within 30, 60 and 120 minutes

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No — Data will be avaiable to be shared on demand. However, statistical analysis and prediction modeling computer code will be made publicly available on GitHub.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.

Of 85 non-industry observational studies under Death, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 245. This study's planned 47 months is below that.

Counting every sponsor, half of 88 studies reached it within 69 months; a quarter within 23 and three quarters within 245.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Canada)
  • CHUM · Montreal, Canada
  • Hôpital du Sacré Coeur · Montreal, Canada
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    2 sites added
    Show 2 added (2 Canada)
    • CHUM · Montreal, Canada
    • Hôpital du Sacré Coeur · Montreal, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07698262
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Myp Sekhon (Division Head, UBC Critical Care Medicine, University of British Columbia) — Principal investigator
First posted
Jul 13, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Rebecca Grey Clinical Research Coordinator
Contact
cerebri.research@ubc.ca
604-875-4111 ext. 68336

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion